Five decades of psoriasis pharmacotherapy map a shift toward targeted immune control
Five decades of psoriasis pharmacotherapy research now read like the history of modern immune medicine. A bibliometric analysis spanning 19,284 publications from 1975 through 2025 charted how the field moved from small, scattered studies into a tightly connected research domain shaped by biologics, pathway-specific agents, and precision-oriented thinking.
The scale alone is striking. Publications increased from just 9 articles in 1975 to 1,638 in 2024, a trajectory that mirrors the growing clinical urgency of treating chronic inflammatory disease with treatments that are both more effective and more mechanistically precise.
Publication growth tracks the rise of biologic-era dermatology
The analysis divided the literature into four developmental phases and then grouped the thematic evolution into three time periods: 1975-2000, 2001-2010, and 2011-2025. Across those eras, psoriasis pharmacotherapy evolved from a largely foundational immunologic enterprise into a mature field built around targeted intervention and evidence synthesis.
Citation impact reached its highest point during 2001-2008, aligning with the arrival of revolutionary biological therapy. That peak is biologically intuitive. Once therapies began selectively interrupting cytokine signaling rather than broadly suppressing inflammation, psoriasis became not only a skin disease to treat, but a model for how mechanism-based drug development could alter chronic immune-mediated illness.
The literature also shows how quickly a therapeutic class can reorganize a field. Early work clustered around basic immunology and generalized treatment approaches. Later work moved into highly specific pathways, first with tumor necrosis factor alpha inhibitors and then with newer agents targeting interleukin-17, interleukin-23, and Janus kinase signaling. In clinical terms, this progression reflects a deeper understanding of the cytokine networks driving keratinocyte activation, systemic inflammation, and persistent disease burden.
The United States led volume, while Canada led citation efficiency
The United States accounted for 5,959 documents, making it the largest contributor by volume. Canada, however, reached the highest citation efficiency at 62.65 citations per document. Volume and influence do not always travel together, and this dataset makes that clear.
Citation efficiency matters in bibliometrics because it can signal concentrated influence, high-impact methodologic work, or a smaller but especially influential national research footprint. Here, Canada’s citation density suggests that its contributions landed disproportionately well within the field’s intellectual core, even though the United States produced the largest body of work overall.
International collaboration was broad and structured rather than diffuse. Seventy countries participated in the network, organized into four regional clusters. The largest collaborative group was a 28-nation alliance spanning Asia-Pacific, Africa, and the Middle East. In practical research terms, psoriasis pharmacotherapy has become a global project, not a series of isolated regional conversations.
From two foundational themes to four consolidated domains
The thematic map is one of the most revealing parts of the analysis. Research began with two foundational themes, expanded into nine specialized domains, and then consolidated into four core areas centered on targeted therapeutics and evidence-based methodologies. That progression suggests a field that has matured in both scientific sophistication and clinical specificity.
Early-stage literature often reflects broad mechanistic exploration, while later-stage literature tends to split into more defined therapeutic and methodological subfields. Here, the field first diversified and then reorganized around a smaller number of mature priorities. This pattern is consistent with medical disciplines that have moved beyond proof-of-concept questions into treatment optimization, comparative effectiveness, and long-term therapeutic selection.
A single sentence captures the clinical significance: psoriasis research no longer revolves only around what inflammation is, but around which molecular node should be blocked, in whom, and with what long-term tradeoff.
AI-guided terminology normalization improved the bibliometric signal
One of the methodological features of the study was AI-enhanced terminology normalization, used to standardize pharmaceutical nomenclature before analysis. In a literature as broad as psoriasis pharmacotherapy, term variation can obscure real scientific patterns. A drug class may appear under multiple naming conventions, and pathway terminology can evolve over time as the field matures.
Normalizing those terms is not a cosmetic step. It improves the fidelity of network mapping, keyword clustering, and temporal trend analysis by reducing the risk that the same concept will fragment across several labels. Combined with VOSviewer version 1.6.20 and the Bibliometrix package, this approach allowed the authors to track how ideas, drug classes, and research priorities moved through the literature over time.
That matters for interpretation. Bibliometric studies are only as reliable as the vocabulary they can successfully unify. Once nomenclature is stabilized, the underlying structure of scientific change becomes easier to see: early immunology gives way to cytokine-specific targeting, and broad therapeutic experimentation narrows into pathways with durable translational relevance.
Psoriasis now serves as a model for precision medicine in inflammatory disease
The conclusions reach beyond dermatology. Over five decades, psoriasis therapeutics research has shifted from a niche area into a central model for innovation in immune-mediated disease. The field now offers a working example of how drug development can move from symptomatic control toward pathway-guided treatment selection.
This evolution has direct implications for other inflammatory conditions. Psoriasis has long been a proving ground for biologic development, and the bibliometric arc described here shows why: it combines a clearly visible clinical phenotype with deep immunologic complexity, making it an ideal setting for testing targeted therapies and studying how evidence accumulates across generations of treatment.
The study also offers a sober reminder about what bibliometrics can and cannot do. It traces scientific attention, collaboration, and thematic drift with impressive breadth, but it does not measure patient-level outcomes, comparative efficacy, or adverse-event burden. Those questions remain the province of clinical trials and long-term observational studies.
Even so, the pattern is unmistakable. The field advanced from broad inflammatory inquiry to a highly organized therapeutic architecture centered on biologics, IL-17 and IL-23 blockade, and JAK inhibitors. Future research will need to determine how these mechanistic gains translate into sustained remission, sequencing decisions, and safer long-term treatment strategies across diverse patient populations.